BR112018070727A2 - novos compostos como agonistas de gpr119 - Google Patents

novos compostos como agonistas de gpr119

Info

Publication number
BR112018070727A2
BR112018070727A2 BR112018070727-9A BR112018070727A BR112018070727A2 BR 112018070727 A2 BR112018070727 A2 BR 112018070727A2 BR 112018070727 A BR112018070727 A BR 112018070727A BR 112018070727 A2 BR112018070727 A2 BR 112018070727A2
Authority
BR
Brazil
Prior art keywords
new compounds
gpr119 agonists
compounds
gpr119
agonists
Prior art date
Application number
BR112018070727-9A
Other languages
English (en)
Other versions
BR112018070727B1 (pt
Inventor
Ishwar Patil Rakesh
Verma Jeevan
Shah Dharmesh
Ali Sazid
Reddy Bapuram Srinivasa
Kumar Rai Santosh
Kumar Anil
Original Assignee
Mankind Pharma Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mankind Pharma Ltd. filed Critical Mankind Pharma Ltd.
Publication of BR112018070727A2 publication Critical patent/BR112018070727A2/pt
Publication of BR112018070727B1 publication Critical patent/BR112018070727B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

a presente invenção refere-se a novos compostos da fórmula (i) como agonista de gpr119, composições que contêm tais compostos e método de preparação dos mesmos.
BR112018070727-9A 2016-04-08 2017-04-05 Compostos e respectivos usos BR112018070727B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201611012425 2016-04-08
IN201611012425 2016-04-08
PCT/IB2017/000471 WO2017175068A1 (en) 2016-04-08 2017-04-05 Thiazolopyridine derivatives as gpr119 agonists

Publications (2)

Publication Number Publication Date
BR112018070727A2 true BR112018070727A2 (pt) 2019-03-06
BR112018070727B1 BR112018070727B1 (pt) 2024-04-16

Family

ID=

Also Published As

Publication number Publication date
CA3020478C (en) 2021-07-20
TW201741318A (zh) 2017-12-01
AU2017246996A1 (en) 2018-11-01
RU2018138050A (ru) 2020-05-12
ZA201807350B (en) 2019-08-28
CN109415381A (zh) 2019-03-01
AU2017246996B2 (en) 2019-11-28
NZ763098A (en) 2023-04-28
JP6831450B2 (ja) 2021-02-17
EP3440087A1 (en) 2019-02-13
US10919915B2 (en) 2021-02-16
RU2018138050A3 (pt) 2020-05-12
AR108101A1 (es) 2018-07-18
AU2020201450A1 (en) 2020-03-19
CN109415381B (zh) 2022-03-25
US20170291910A1 (en) 2017-10-12
WO2017175068A1 (en) 2017-10-12
US10526345B2 (en) 2020-01-07
ES2926625T3 (es) 2022-10-27
CA3020478A1 (en) 2017-10-12
RU2749111C2 (ru) 2021-06-04
WO2017175068A8 (en) 2018-05-11
NZ746954A (en) 2020-04-24
AU2020201450B2 (en) 2021-07-01
EP3440087B1 (en) 2022-08-10
US20200040006A1 (en) 2020-02-06
TWI657091B (zh) 2019-04-21
JP2019513834A (ja) 2019-05-30
MX2018012087A (es) 2019-06-12

Similar Documents

Publication Publication Date Title
UY36705A (es) Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj
MX2018012087A (es) Compuestos agonistas de gpr119 y metodo para tratar enfermedades y afecciones mediado a traves de gpr119.
BR112018068341A2 (pt) 6-hidróxi-4-oxo-1,4-di-hidropirimidina-5-carboxamidas como agonistas de apj
CO2018006662A2 (es) Agonistas del receptor de apelina y métodos de uso
BR112018007395A2 (pt) 2,4-di-hidróxi-nicotinamidas como agonistas de apj
CO2018007221A2 (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj)
CR20180563A (es) Nuevos derivados piperidinilo sustituidos con hetero(arilo), un proceso para su preparación y composiciones farmacéuticas que lo contienen
EA201890749A1 (ru) ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ (ACC) И ИХ ПРИМЕНЕНИЕ
BR112018067538A2 (pt) inibidores de ire1-alfa de pequenas moléculas
BR112016014020A8 (pt) moduladores de tetra-hidropiridopirazinas de gpr6.
EA201591961A1 (ru) Ингибиторы акк и их применение
MX2018012085A (es) Compuestos agonistas de gpr119 y metodo para tratar enfermedades y afecciones mediado a traves de gpr119.
EA201591959A1 (ru) Ингибиторы акк и их применение
ECSP15045801A (es) Inhibidores de la phd de 6–(5–hidroxi–1h–pirazol–1–il)nicotinamida
EA201591960A1 (ru) Ингибиторы акк и их применение
BR112016028476A8 (pt) compostos, composição, uso de um composto e método para o combate dos fungos nocivos
EA201591962A1 (ru) Ингибиторы акк и их применение
BR112018011526A2 (pt) compostos policíclicos como inibidores da tirosina quinase de bruton
BR112017010311A2 (pt) 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139
EA201790570A1 (ru) Модуляторы р2х7
BR112016002638A2 (pt) novos aza-oxo-indóis para o tratamento e profilaxia de infecção pelo virus sincicial respiratório
BR112018076734A2 (pt) compostos heterocíclicos anti-infecciosos e usos dos mesmos
BR112016018418A2 (pt) Composto, uso do mesmo, e composição farmacêutica
BR112016028948A2 (pt) ?composição bifásica?
BR112017013194A2 (pt) síntese total de trioxacarcina dc-45-a2 e preparação de análogos de trioxacarcina

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/04/2017, OBSERVADAS AS CONDICOES LEGAIS